Intuitive Surgical stock fell to a 52-week low on July 16 as the robotic surgery company reported second-quarter earnings that beat analyst estimates but failed to reverse a broader market skepticism toward the company’s growth prospects.
The company reported Q2 2026 earnings per share of $2.41, meeting expectations in a quarter marked by solid operational performance. Yet the stock’s decline reflects investor concerns that have mounted throughout the year as multiple Wall Street analysts trimmed their price targets ahead of the earnings release.
Intuitive Surgical shares have fallen roughly 25 percent in 2026 to date, with the company trading significantly below its $560 analyst price target, according to 24/7 Wall Street. The pressure on the stock accelerated in mid-July when TD Cowen cut its price target to $520 from $585 while maintaining a Buy rating, citing competitive pressures and other headwinds in the surgical robotics market.
The sell-off reflects a shift in market sentiment from earlier in the year. When Intuitive Surgical reported first-quarter 2026 results in April, the company beat on earnings per share with a result of $2.50 versus analyst expectations of $2.08, and the stock gained 7 percent in response. That quarter also saw management raise full-year 2026 guidance for worldwide da Vinci procedure growth to a range of 13.5 percent to 15.5 percent.
The contrast between Q1’s market reception and Q2’s reaction highlights how earnings beats alone no longer guarantee positive stock performance for the medical device maker. Investors appear focused on forward guidance and margin pressures—including tariff impacts that have weighed on the company’s profitability outlook—rather than backward-looking quarterly results.
Sources
- public.com — Q2 2026 actual EPS of $2.41
- scanx.trade — Intuitive Surgical shares fell to 52-week low on July 16, 2026, pressured by analyst price-target cuts
- 24/7 Wall Street — Stock down 25-27 percent year-to-date, trading below $560 analyst target with 35 percent upside potential
- MarketBeat — TD Cowen cut price target to $520 from $585 while maintaining Buy rating
- TIKR.com — Q1 2026 EPS beat of $2.50 versus estimate, 7 percent stock gain in April
- Seeking Alpha — Q1 2026 guidance raised to 13.5–15.5 percent da Vinci procedure growth
